Pharma Focus Asia

Biocytogen Pharmaceuticals and Pheon Therapeutics Announced a License Agreement

Thursday, July 06, 2023

Biocytogen Pharmaceuticals announced a licence agreement with Pheon Therapeutics regarding the development and commercialisation of an antibody.

Under the terms of the agreement, Pheon will develop and commercialise an antibody developed on Biocytogen's proprietary RenMiceTM platforms.

As part of the agreement, Biocytogen will receive an upfront payment and will also be eligible for milestone payments during the development and commercialisation process. Additionally, Biocytogen will receive single-digit royalties on net sales.

The licence agreement between Biocytogen and Pheon represents a significant expansion of Pheon's pipeline and will contribute to their ability to develop the next generation of ADCs (antibody-drug conjugates).

The combination of strengths between fully human antibody discovery and ADC (Antibody-Drug Conjugate) technologies has the potential to greatly accelerate the development of new medicines that can benefit patients.

RenMiceTM platforms offer a unique approach by completely replacing the variable genes of human antibodies in situ. RenMiceTM platforms has the ability to generate antibodies with low immunogenicity. Immunogenicity refers to the potential of an antibody to elicit an immune response in the body, which can reduce its effectiveness and lead to unwanted side effects.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024